Real-World Evidence Accelerator Facing Data Access Challenges For Vaccines - Scrip News for Pink Sheet

The Reagan-Udall Foundation’s Evidence Accelerator program is navigating novel data flow challenges when it comes to assessing the safety and effectiveness of COVID-19 vaccines. The Evidence Accelerator was launched in April 2020 by Reagan-Udall, a foundation that supports the US Food and Drug Administration, and Friends of Cancer Research to identify key questions about the COVD-19 pandemic that could be addressed through real-world data and real-world evidence and pressure-testing approaches to address those questions.
Coverage

Reagan-Udall Foundation for the FDA Announces Two New Board Members

(June 3, 2021) The Reagan-Udall Foundation for the Food and Drug Administration (FDA Foundation) is expanding its leadership with the addition of two new Board members: Christie Boutte, PharmD, RPh, Senior Vice President of Reimbursement, Innovation, and Advocacy for the National Association of Chain Drug Stores (NACDS) and Phil Febbo, MD, Chief Medical Officer for Illumina. 

Announcements

2021 Annual Public Meeting

On May 12, 2021, more than 100 stakeholders joined Reagan-Udall Foundation for the FDA Board of Directors for their Annual Public Meeting. The discussion centered on how public-private partnerships help advance the mission of FDA. Board members joined FDA leaders to highlight the impact of cross-cutting collaborations – especially in the last year as we faced unprecedented public health challenges. 

Annual Public Meeting
Subscribe to